Sökning: WFRF:(Lund Peter) >
Eligibility for sot...
-
Becher, Peter MoritzKarolinska Inst, Sweden; Univ Med Ctr Hamburg Eppendorf, Germany; German Ctr Cardiovasc Res DZHK, Germany
(författare)
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
2023-01-30
-
OXFORD UNIV PRESS,2023
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-192525
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-192525URI
-
https://doi.org/10.1093/ehjcvp/pvad012DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:152035466URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Aims The SOLOIST-WHF trial demonstrated efficacy of sotagliflozin in patients with type 2 diabetes mellitus (T2DM) and recent worsening heart failure (HF) regardless of ejection fraction (EF). Selection criteria in trials may limit their generalizability. Therefore, we aimed to investigate eligibility for sotagliflozin based on the SOLOIST-WHF criteria in a real-world HF population. Methods and results SOLOIST-WHF criteria were applied to patients stabilized after HF hospitalization in the Swedish HF Registry according to (i) literal scenario (all inclusion/exclusion criteria) or (ii) pragmatic scenario (only criteria likely to influence treatment decisions). Of 5453 inpatients with T2DM and recent worsening HF, 51.4% had reduced EF (HFrEF), 19.1% mildly reduced (HFmrEF), and 29.5% preserved EF (HFpEF). Eligibility (literal) was: 27.2% (32.4% in HFrEF, 24.7% in HFmrEF, 19.7% in HFpEF) and eligibility (pragmatic) was 62.8% (69.1%, 60.3%, 53.4%, respectively). In the literal scenario, criteria limiting eligibility were HF duration <3 months, eGFR <30 ml/min/1.73 m(2), age >85 years, acute coronary syndrome <3 months, and insufficiently high N-terminal pro-B-type natriuretic peptide levels. Eligible vs. non-eligible patients had more severe HF, higher cardiovascular (CV) comorbidity burden, higher use of HF treatments, and higher event rates (all-cause death 30.8 vs. 27.2 per 100 patient-years, CV death 19.1 vs. 16.6, and HF hospitalization 36.7 vs. 24.0). Conclusion In this large, real-world HF cohort with T2DM, similar to 1/3 of patients were eligible for sotagliflozin in the literal and similar to 2/3 of patients in the pragmatic scenario. Eligible patients had more severe HF and higher event rates, in particular CV and HF events.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Savarese, GianluigiKarolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
(författare)
-
Benson, LinaKarolinska Institutet,Karolinska Inst, Sweden
(författare)
-
Dahlström, UlfLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US(Swepub:liu)ulfda85
(författare)
-
Karlström, PatricLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Ryhov Cty Hosp Reg Jonkoping Cty, Sweden(Swepub:liu)patka84
(författare)
-
Mol, Peter G. M.Univ Groningen, Netherlands,Univ Brescia, Italy
(författare)
-
Metra, MarcoUniv Brescia, Italy
(författare)
-
Bhatt, Deepak L.Mt Sinai Hlth Syst, NY 10029 USA
(författare)
-
Pitt, BertramUniv Michigan, MI 48109 USA
(författare)
-
Lund, Lars H.Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden
(författare)
-
Karolinska InstitutetKarolinska Inst, Sweden; Univ Med Ctr Hamburg Eppendorf, Germany; German Ctr Cardiovasc Res DZHK, Germany
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:European Heart Journal - Cardiovascular Pharmacotherapy: OXFORD UNIV PRESS9:4, s. 343-3522055-68372055-6845
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Becher, Peter Mo ...
-
Savarese, Gianlu ...
-
Benson, Lina
-
Dahlström, Ulf
-
Karlström, Patri ...
-
Mol, Peter G. M.
-
visa fler...
-
Metra, Marco
-
Bhatt, Deepak L.
-
Pitt, Bertram
-
Lund, Lars H.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
European Heart J ...
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet